So what if I told youthat an analyst who follows TH wrote a report today and decided not to mention anything about either the financing or the phase 1a data. Instead, the analyst decided to focus their report first on Egrifta, then NASH and then Trogarzo. I have to admit that cancer did get a brief mention in the "Risk Factors" section where the analyst made this comment: "2) increased focus on drug development as TH makes
progress on its oncology assets".
Obviously, you probably think I am drunk or doinig drugs to say such a ridiculous thing! Sadly, I am completely lucid and am just reporting accurately on how the NBF analyst crafted his THTX report today.
The blame for this is obviously partly on the analyst but it is apparent the company's failure to maintain a decent relationship with this analyst or any of the others is what leads to such absurdity in the end. You might think the analyst is really stupid but I don't think that is the case. He likely has just had it with how bad TH has been over a long period of time on engaging the capital markets and how they have let the stock price bleed out in recent months in an info vacuum by holding back that phase 1a data for months. TH could have been giving regular updates as the patients they spoke about today moved through the trial. Maybe there was a good reason to not do so, but I am not aware of it.
$288,000 dollars worth of THTX traded hands today on the great news we got today that significantly derisked the future of the company - that is it! I am not sure how that can actually be true but the depths to which the company's engagement with the capital markets has reached is breathtaking. We thought there was a problem a year ago and two years ago and three years ago and so on. Shareholders asked for a new board memeber with expertise in the capital markets to be added, which they graciously did, but the situation, which seemed like it could not get any worse, has gotten worse still.
It was a great day for THTX. Too bad so few investors actually noticed.